Ovid Therapeutics Inc.OVIDEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
OVID Q4 FY2025 Key Financial Metrics
Revenue
$718.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
844.7%
Ovid Therapeutics Inc. Q4 FY2025 Financial Summary
Ovid Therapeutics Inc. reported revenue of $718.0K (up 844.7% YoY) for Q4 FY2025, with a net profit of N/A (up 204.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $718.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Ovid Therapeutics Inc. Annual Revenue by Year
Ovid Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.3M).
Ovid Therapeutics Inc. Quarterly Revenue & Net Profit History
Ovid Therapeutics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $718.0K | +844.7% | N/A | N/A |
| Q3 FY2025 | $132.0K | -23.7% | $-12.2M | -9210.6% |
| Q2 FY2025 | $6.3M | +3611.2% | $-4.7M | -74.7% |
| Q1 FY2025 | $130.0K | -12.2% | $-10.2M | -7873.1% |
| Q4 FY2024 | $76.0K | -46.5% | N/A | N/A |
| Q3 FY2024 | $173.0K | +58.7% | $-14.0M | -8096.0% |
| Q2 FY2024 | $169.0K | +125.3% | $8.5M | 5042.0% |
| Q1 FY2024 | $148.0K | +124.2% | $-11.7M | -7901.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $148000 | $169000 | $173000 | $76000 | $130000 | $6.3M | $132000 | $718000 |
| YoY Growth | 124.2% | 125.3% | 58.7% | -46.5% | -12.2% | 3611.2% | -23.7% | 844.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $131.6M | $118.1M | $102.7M | $92.2M | $81.7M | $77.4M | $63.8M | $150.9M |
| Liabilities | $53.3M | $29.2M | $26.4M | $23.9M | $22.4M | $21.6M | $19.1M | $20.3M |
| Equity | $78.3M | $88.9M | $76.3M | $68.2M | $59.3M | $55.8M | $44.7M | $130.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.7M | $-14.3M | $-15.0M | $-56.0M | $-10.3M | $-4.8M | $-12.9M | $-38.3M |